GET DAILY SIGNALSOramed Pharmaceuticals (ORMP): Can the Stock Reach $7 for +74% Upside?
Key Takeaways
- The $7.00 central target comes from public market discussion, mainly one published analyst price objective, rather than a broad consensus.
- With ORMP near $4.03, a move to $7.00 would imply roughly 74% upside, a substantial gain for any stock.
- Sell-side coverage remains limited, with one $7.00 target often referenced and a Fintel average near $7.14 in a $7.07–$7.35 range.
- The strongest support lies in the oral-insulin platform's potential within a narrower patient subset after the 2023 Phase 3 setback.
- Primary risks include clinical and regulatory uncertainty, a research-stage model, and earnings figures influenced by non-recurring items.
- For updates on Major News, Today's Price Move, Forecast, and Earnings, check those dedicated pages.
Analyst Coverage and the Origin of the $7 Objective
Oramed lacks sufficient current analyst targets for a robust multi-analyst consensus, so the $7 figure here represents a publicly discussed objective rather than an official average. Sources such as Yahoo Finance and Barron's note a single $7.00 one-year target, with Barron's labeling the lone rating as Hold. Fintel shows an average near $7.14 from a $7.07–$7.35 range, while Simply Wall St lists $6.25 from one analyst. The variation highlights that only a small number of analysts follow the name, with estimates shifting as the pipeline evolved.
Current Market Position and Path to the Target
As of mid-November 2026, ORMP trades around $4.03, with a market capitalization near $168 million and a 52-week range of $2.10 to $5.47. Reaching $7.00 would mean a gain of about 74%, pushing the stock well above its 52-week high. The reported trailing EPS of roughly $4.13 and sub-1x P/E ratio do not reliably indicate profitability, as results include non-recurring, non-operating items rather than ongoing product revenue. Any realistic path to $7 hinges on fresh clinical validation of ORMD-0801, not present earnings.
Factors That Could Support a Move Higher
The key catalyst remains clinical progress. Following the ORMD-0801 miss of its primary endpoint in a Phase 3 type 2 diabetes trial in early 2023, management pinpointed a potentially responsive subset—elderly patients with low BMI and high baseline HbA1c—and started a new, smaller trial focused on that group. Positive signals from a Chinese partner support the notion that the oral-delivery platform could still succeed in this narrower population. Recent commentary also describes the company as well-capitalized, which lowers near-term dilution risk and provides runway for the trial. Success here could reopen a meaningful oral-insulin opportunity and underpin a higher valuation.
Risks That Could Keep the Target Out of Reach
The challenges are straightforward. Oramed has no meaningful product revenue and a prior failed pivotal trial, leaving the stock highly speculative. Another clinical miss, regulatory delays, or weak subset data would weaken the case. Competition in oral diabetes therapies is strong, including oral GLP-1 programs from major pharmaceutical firms. In addition, because reported earnings have been boosted by one-time gains, any market reevaluation of sustainable earnings power could weigh on the shares even without a clinical event.
Technical Levels and Market Structure
The stock sits just below its 200-day moving average near $4.05 and below its 50-day average near $4.41, showing a modest pullback from the August 2026 high of $5.47. That $5.47 level, along with the $5.00 mark, forms notable resistance on any rally. On the downside, the $3.84–$3.90 zone has provided support recently. A move toward $7 would likely require clearing both the $5.00 and $5.47 levels first, suggesting the target would come only after a sustained breakout rather than a single event.
Time Horizon and Items to Monitor
Analyst price targets generally look out about 12 months, though limited coverage means no firm timeline applies here. Key items to watch include the next quarterly report, expected in November 2026, updates on the narrower-subset trial and partner data, cash position and financing moves, and any shifts in the few existing analyst targets. Clinical readouts, not earnings, remain the main driver for the share price.
Integrating AI Tools Into Everyday Analysis
When reviewing names like this, I often run a quick check with Tickeron’s AI Screener to compare the stock against peers in the sector. I also looked at signals from the AI Trend Prediction Engine to gauge longer-term patterns. These short checks help round out the broader picture without replacing fundamental work.
My Experience With Tickeron’s AI Daily Buy/Sell Signals
In my own research process, Tickeron’s AI Daily Buy/Sell Signals have been a useful addition. The tool applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on market conditions, technical factors, and AI analysis. It helps me identify opportunities and track shifts more efficiently than manual reviews alone, fitting naturally alongside clinical and financial review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ORMP's RSI Oscillator ascends from oversold territory
The RSI Indicator for ORMP moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 26 of the 29 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 62 cases where ORMP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Moving Average Convergence Divergence (MACD) for ORMP just turned positive on November 10, 2026. Looking at past instances where ORMP's MACD turned positive, the stock continued to rise in 38 of 49 cases over the following month. The odds of a continued upward trend are 78%.
ORMP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ORMP as a result. In 72 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ORMP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for ORMP entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. ORMP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.506) is normal, around the industry mean (3.498). P/E Ratio (0.910) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.259) settles around the average of (130.981) among similar stocks. P/S Ratio (90.909) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ORMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in pharmaceutical preparations
Industry Biotechnology
Advertisement